A groundbreaking phase II clinical trial, known as the SAVANNAH study, has revealed significant advancements in the treatment of advanced non-small cell lung cancer (NSCLC) with specific genetic mutations. The combination of savolitinib and osimertinib has shown promising results in patients who developed resistance to first-line osimertinib therapy.
Study Results Highlight Efficacy
The study enrolled 365 patients with EGFR-mutated, advanced NSCLC exhibiting MET overexpression or amplification. Out of these, 341 patients received the savolitinib and osimertinib combination. Focusing on the primary efficacy population of 80 patients, the treatment achieved an objective response rate (ORR) of 56.3%. Additionally, the median duration of response was 7.1 months, and the median progression-free survival (PFS) reached 7.4 months, indicating a substantial impact on disease progression.
Safety Profile and Adverse Effects
The combination therapy was generally well-tolerated among participants. The most frequently reported adverse events included peripheral edema (46.0%), nausea (40.5%), and diarrhea (23.2%). Despite these side effects, the overall safety profile supports the use of savolitinib and osimertinib as a viable treatment option for this patient population.
- High ORR suggests effective targeting of MET-driven resistance mechanisms.
- Durable responses indicate sustained control over tumor progression.
- Manageable side effects enhance the treatment’s clinical applicability.
The findings from the SAVANNAH study position the savolitinib and osimertinib combination as a robust oral targeted therapy for patients with MET-positive EGFR-mutated NSCLC who have developed resistance to previous osimertinib treatment. This innovative approach offers a new avenue for improving patient outcomes in a challenging therapeutic landscape.
Advanced NSCLC patients with MET alterations now have a promising treatment alternative that not only addresses the resistance to existing therapies but also provides a manageable safety profile. Healthcare providers can consider incorporating this combination into their treatment protocols, potentially enhancing the quality of life and survival rates for individuals battling this aggressive form of lung cancer.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
